基于药物化学的新型治疗药物,用于阿尔茨海默氏症患者的陶病
Subashchandrabose Chinnathambi1, Sneha Malik1, Madhura Chandrashekar1
1Department of Neurochemistry, National Institute of Mental Health and Neuro Sciences Hospital (NIMHANS), Institute of National Importance, Bangalore, Karnataka, India.
Advances in protein chemistry and structural biology
|September 19, 2025
概括
尽管有超过一个世纪的研究,阿尔茨海默氏症 (AD) 缺乏治疗方法. 然而,各种化合物,包括小分子,天然产品,树枝状物和金属基剂,在治疗AD症状和进展方面表现有前途.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 材料科学 材料科学 材料科学
背景情况:
- 阿尔茨海默病 (AD) 的研究已经持续了100多年,没有确定的治疗方法.
- 目前正在研究许多治疗策略,以管理AD症状,缓慢进展或反作用.
研究的目的:
- 审查和突出阿尔茨海默病的有前途的治疗化合物和策略.
- 强调多样化分子结构在阿兹海默氏症治疗中的潜力.
主要方法:
- 探索小分子 (例如,托卢伊丁蓝色,黑素).
- 对自然化合物的治疗潜力的研究.
- 评价树枝状体作为药物输送系统和对Tau和AD的直接治疗方法.
- 在AD治疗中对金属复合物和纳米颗粒的评估.
- 合成和评估一种双功能合剂的铜,向陶和胺-β (Aβ).
主要成果:
- 像托卢伊丁蓝和黑激素这样的小分子对阿尔茨海默病具有实用性.
- 自然化合物对阿尔茨海默病具有显著的治疗潜力.
- 登德里默表现出有效性,既是药物输送系统,也是对Tau和AD的直接治疗方法.
- 金属复合物和纳米粒子为AD提供了可行的治疗选择.
- 一种新的双功能化合物有效化铜,并向Tau和Aβ.
结论:
- 广泛的化合物,包括小分子,天然产品,树枝体和金属基剂,显示出对阿尔茨海默病治疗的希望.
- 进一步的临床试验对于推进有效的阿尔茨海默氏症治疗方法至关重要.
- 针对tau和amyloid-β (Aβ) 途径,使用像双功能合剂这样的新药是一种有前途的方向.
相关概念视频
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
560
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
560


